PTGS2 and Hand-foot syndrome: A meta-analysis of randomized controlled trials suggested that celecoxib, a cyclooxygenase-2 selective inhibitor, reduced the risk of all-grade or moderate-to-severe HFS caused by capecitabine and sorafenib12.